Visuri

Visuri operates at the intersection of medical devices, digital health, and neuromuscular rehabilitation. Its stated differentiation is the combination of neuromuscular stimulation and monitoring in ReCARE® Plus, together with remote case management for clinical teams. ANVISA registration for ICU use gives the product a defined critical-care application, while its stated use across adult and pediatric intensive care, neurology, vascular care, and physiotherapy suggests a broader clinical remit. Connect 5.0 extends the portfolio into professionally assisted remote rehabilitation and received the 8th eAWARDS Brasil from Fundação NTT Data. In contrast with a profile centered only on consumer wellness or standalone telehealth, Visuri’s described offering combines physical stimulation devices with monitoring and remote clinical support. The extent to which this translates into a durable commercial advantage remains unclear without evidence on deployments, regulatory coverage beyond the stated ICU registration, or comparative results.

Visuri’s portfolio includes ReCARE® Plus, a neuromuscular activation and monitoring system for critical-care applications, and Connect 5.0, a platform for professionally assisted remote rehabilitation. This combination points to activity across both institutional care and remote treatment workflows. The company also describes applications spanning adult and pediatric intensive care, neurology, vascular care, and physiotherapy. As a result, the evidence supports a description of the product scope, not a conclusion that the company is accelerating or scaling. Further dated information on product deployment, customer growth, financing, and team expansion would be needed to assess commercial trajectory.